Dapagliflozin-Metformin in Obese T2D After GLP-RA: Assessing Newer Possibilities- Dr Bharat Saboo

Globally and in India, T2DM prevalence continues to rise, with obesity as one of its most important clinical drivers, reported in nearly 60-90% of Indian patients with T2DM. GLP-1 receptor agonists and dual GIP/GLP-1 agonists, the former more so with their improved accessibility in India over the last few months, have reshaped obesity-focused diabetes care by improving glycemic control, promoting weight loss, and offering cardiovascular benefits. However, discontinuation of GLP-RA is often followed by weight regain and loss of cardiometabolic gains, reflecting obesity's chronic, relapsing nature. In this context, the dapagliflozin–metformin fixed-dose combination offers a practical oral option for continued glucose, weight, and CV risk management in T2D. 

Post-GLP-1RA Discontinuation- Worsening Cardio-Metabolic Trajectory

Cessation of GLP-1RA therapy precipitates rapid reversal of metabolic gains. In SURMOUNT-4, participants who achieved ~20.9% body weight reduction regained ~14.0% of total body weight within 52 weeks, surrendering approximately 67% of their treatment-induced loss. A 2026 meta-regression analysis (6 RCTs, n=3,236) confirmed this pattern, showing that 60% of weight loss is regained within one year, with most regain occurring within the first 23 weeks, eventually plateauing at 75.3% of the original weight lost.

The rebound extends well beyond weight. HbA1c rises sharply, approximately 50% of glycaemic benefit is lost within 8–12 weeks post-cessation. Systolic BP recovers 70–80% of its reduction within 12 weeks; lipid and cardiometabolic benefits regress in parallel, restoring pre-treatment cardiovascular risk. In SURMOUNT-4, HbA1c increased by 0.14 to 0.35%, systolic BP by 6.8 to 10.4 mmHg, and diastolic BP by 1.6 to 4.3 mmHg within 52 weeks of withdrawal, with greater regain driving a larger reversal of cardiometabolic gains. Managing these cardio-metabolic gains demands a durable, maintenance-oriented strategy.

Dapagliflozin-Metformin Combination: Complementary Actions Supporting Gluco-Metabolic & CV Protection Effects

Metformin suppresses hepatic gluconeogenesis (via mitochondrial glycerophosphate dehydrogenase inhibition and AMPK activation) and improves peripheral insulin sensitivity — directly countering the fasting hyperglycaemia and insulin resistance. Additionally, metformin enhances endogenous GLP-1 secretion from intestinal L-cells via muscarinic M3 and gastrin-releasing peptide receptor pathways, bridging the incretin gap. Latest evidence suggests metformin exerts glucose-regulating effects by interacting with the central VMH–Rap1 pathway to optimize autonomic regulation in addition to its peripheral actions.

Dapagliflozin complements this via insulin-independent renal SGLT2 inhibition, producing substantial glucosuria with net caloric deficit and reducing both visceral and subcutaneous adipose tissue (standardized mean difference −0.406 and −0.439, respectively); thus targeting pathogenic fat recovery. For blood pressure, dapagliflozin lowers systolic BP by ~4–5 mmHg acutely through osmotic diuresis and natriuresis, and chronically via reduced sympathetic nervous system activity and improved arterial stiffness. Cardiovascular protection is established: in DECLARE-TIMI 58, dapagliflozin reduced the co-primary endpoint of cardiovascular death or hospitalization for heart failure by 17% (HR 0.83; P=0.005) versus placebo. ,

These mechanisms are complementary and non-overlapping: metformin acts on the liver and gut; dapagliflozin acts on kidney and adipose tissue. As a single-pill FDC, they offer a maintenance-oriented strategy, sustaining glycaemic control, supporting weight loss, preserving BP gains, and protecting against cardiovascular risk.

Dapagliflozin and Metformin Clinical Evidence: Effect on Weight, Adipose, Glucose & CV Risk

Dapagliflozin Metformin FDC- Cardio-Metabolic Benefit in Indian T2D: A multicenter Indian study (n=481, 6-month follow-up) evaluating dapagliflozin–metformin FDC as initial T2DM therapy demonstrated weight reduction of 4.2 kg, fasting glucose lowering of 21.4 mg/dL, systolic BP reduction of 10.7 mmHg and diastolic BP of 6.6 mmHg (all p<0.0001), alongside eGFR improvement of 1.9 mL/min/1.73 m² (p<0.0001).

This evidence indicates the potential of Dapagliflozin and Metformin in mitigating the cardio-metabolic risks associated with GLP-RA discontinuation, with both agents possessing relevant weight-lowering effects and CV safety.

SGLT2i – Effect on Fat Distribution & Weight Outcomes: A 2026 network meta-analysis (41 RCTs, n=2,741) suggests SGLT2 inhibitors as the most favorable glucose-lowering class for visceral adipose tissue reduction (SMD −0.90, 95% CI −1.32 to −0.47), outperforming GLP-1RAs (SMD −0.66, 95% CI −1.22 to −0.10). For body weight, SGLT2 inhibitors achieved −3.20 kg (95% CI −4.69 to −1.72) and waist circumference −2.96 cm (95% CI −4.99 to −0.92), significant reductions addressing central adiposity, therapeutic effects relevant to post-incretin therapy withdrawal. SUCRA rankings placed SGLT2 inhibitors among the top three most effective agents for favourable VAT, weight, and waist circumference benefit.

Dapagliflozin Metformin FDC Consideration in Obese T2D- Indian Clinician Considerations & Safety

Indian Clinician Preferences: An Indian KAP clinical survey of 914 clinicians found that dapagliflozin–metformin FDC was the preferred initial combination for overweight T2DM patients by 68.3% of physicians, driven by weight loss, glycaemic control, and cardiorenal benefits. Pill burden and noncompliance were identified as major barriers by 62.4% and 73.3% of clinicians, respectively, which were addressed by the use of fixed-dose combination therapy. Single-pill FDC simplifies regimens, reduces pill burden, and improves adherence versus free combinations; critical for sustaining metabolic gains in the post-incretin maintenance phase.

Real-World Safety- DONATE Post-Hoc Analysis: In the DONATE post-hoc analysis (n=2,990), 72.4% of patients on dapagliflozin received concomitant metformin. The dapagliflozin–metformin dual-therapy subgroup showed adverse events in 26.7%, serious adverse events in 2.5%, and discontinuation due to adverse events in only 1.9% — all numerically lower than the total population and most other dual-therapy combinations, with metabolic improvements versus baseline.

Figure: Dapagliflozin Metformin: Consideration in T2D post-GLP RA

Key Takeaways

● Post-GLP-1RA discontinuation triggers rapid metabolic rebound with 60% weight loss regained within one year and an increase in HbA1c, blood pressure, and cardiovascular risk.

● Dapagliflozin metformin FDC combines complementary non-overlapping mechanisms where metformin suppresses hepatic gluconeogenesis and enhances gut GLP-1 secretion while dapagliflozin reduces weight, with favourable effects on visceral adiposity and blood pressure.

● Real-world Indian cohorts have demonstrated dapagliflozin metformin FDC efficacy, with 4.2 kg weight reduction and 21.4 mg/dL fasting glucose lowering, with 68.3% of Indian physicians preferring the FDC for overweight/obese T2DM patients.

● Dapagliflozin metformin FDC seems a pragmatic strategy to help address the cardiometabolic consequences following GLP-RA discontinuation in obese individuals with T2D, while maintaining favourable effects on body weight and cardiovascular safety, when indicated.

Abbreviations: BP- Blood pressure, CI — Confidence interval, CV/CVD — Cardiovascular/cardiovascular disease, DECLARE-TIMI 58 — Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure and Renal Disease in Patients With Type 2 Diabetes (trial), DBP — Diastolic blood pressure, DONATE — Post-hoc analysis of dapagliflozin real-world adverse events and safety outcomes, eGFR — Estimated glomerular filtration rate (kidney function measure). FDC — Fixed-dose combination, FG — Fasting glucose, GIP — Glucose-dependent insulinotropic polypeptide, GLP-1/GLP-1RA — Glucagon-like peptide-1/glucagon-like peptide-1 receptor agonist, HbA1c — Glycated hemoglobin, HR — Hazard ratio, KAP — Knowledge, attitudes, and practices (survey), L-cells — Intestinal enteroendocrine cells that secrete GLP-1, RCT — Randomized controlled trial, SAE — Serious adverse event, SBP — Systolic blood pressure, SGLT2i — Sodium-glucose cotransporter-2 inhibitor, SUCRA — Surface under the cumulative ranking curve (network meta-analysis ranking), SURMOUNT-4 — Semaglutide Unrelated to Eating Disorder: Impact in Real-World Management Outcomes in Tirzepatide-Treated Type 2 Diabetes (trial), T2D/T2DM — Type 2 diabetes/type 2 diabetes mellitus, VAT — Visceral adipose tissue (central/abdominal fat), SAT — Subcutaneous adipose tissue (under-skin fat), WC — Waist circumference, VMH-Rap1 -VMH-Rap1 — Ventromedial hypothalamus–Ras-proximate-1